Clinical Trials Logo
  1. Home
  2. Recurrent Pregnancy Loss
  3. NCT03174951

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss

Recurrent Pregnancy Loss Clinical Trial

Official title:
Effect of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss With Immunological Causes

Clinical Trial Summary

Miscarriage occurs in about 1-2% of human pregnancies and is one of the common pregnancy problems before 12 weeks of pregnancy. Anatomical and chromosomal abnormalities, microbial factors and auto and alloimmune reactions have been speculated to attribute in recurrent miscarriage. Unexplained recurrent miscarriage (URM) is defined as three or more repeated abortions, probably caused by maternal immunological rejection . Given that maternal immune system encounters semi-allogeneic fetus, pregnancy outcome is associated with the interaction between maternal immune system and immuno-regulatory capability of the fetus. Effectiveness of treatment approaches in RM patients has been controversial and remained to be discovered. Immunomodulatory agents such as corticosteroids and allogeneic lymphocyte immunization showed variable success rates in RM patients. Therapeutic effects of IVIG in unexplained RM is controversial and most positive results were obtained from the trials in RM women with cellular immune abnormalities, such as increased NK cell level and/or cytotoxicity, and T cell abnormalities. Previous studies have shown that the incidence of genetic abnormalities in children who have received immunosuppressive drugs such as IVIg like normal people and normal society. In this study we used IVIg at the time of positive pregnancy,400 mg/kg IVIG was administered intravenously. Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation to suppress the immune system in patients with immunological causes of RPL and the results will be compared with a control group that did not receive any type of drug.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03174951
Study type Interventional
Source Tabriz University of Medical Sciences
Contact
Status Completed
Phase Phase 2
Start date September 20, 2016
Completion date June 20, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT04718233 - Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss Phase 2
Recruiting NCT01946945 - Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis Phase 2
Completed NCT02572154 - Sperm DNA Fragmentation in Recurrent Pregnancy Loss N/A
Recruiting NCT05444283 - Genomic Predictors of Recurrent Pregnancy Loss
Active, not recruiting NCT04621773 - Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
Recruiting NCT02990403 - The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss Phase 4
Recruiting NCT02990390 - The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla N/A
Not yet recruiting NCT05612620 - Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05520112 - Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells Phase 1/Phase 2
Suspended NCT04397042 - SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
Not yet recruiting NCT05341856 - Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL Early Phase 1
Recruiting NCT06007560 - Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss N/A
Completed NCT02386384 - TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure N/A
Recruiting NCT01635426 - Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages Phase 2/Phase 3
Suspended NCT01546350 - Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH Phase 2
Completed NCT00721591 - Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy N/A
Terminated NCT00564174 - Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT N/A
Completed NCT04455256 - Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05237843 - Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss Phase 1
Recruiting NCT02144064 - Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin Phase 3